Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery

Advanced Drug Delivery Reviews

Volumn 65, Issue 3, 2013, Pages 336-341

  Yeo, Ronne Wee Yeh ^a,b   Lai, Ruenn Chai ^a   Zhang, Bin ^a   Tan, Soon Sim ^a   Yin, Yijun ^a   Teh, Bao Ju ^a   Lim, Sai Kiang ^a,b  

^a INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Drug delivery; Exosomes; Mesenchymal stem cells

Indexed keywords

BIOMEDICAL RESEARCH; DISEASE PROGRESSION; DRUG DELIVERY VEHICLES; EXOSOMES; HUMAN MESENCHYMAL STEM CELLS; MESENCHYMAL STEM CELL; POTENTIAL TARGETS; THERAPEUTIC INTERVENTION;

CELL CULTURE; STEM CELLS;

DRUG DELIVERY;

LIPOSOME; MESSENGER RNA; SMALL INTERFERING RNA;

AMINO ACID SEQUENCE; BLOOD BRAIN BARRIER; CELL EXPANSION; CELL FUNCTION; CELL IMMORTALIZATION; CELL LINE; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EFFECTOR CELL; EXOSOME; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MEDICAL RESEARCH; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; RETICULOCYTE; REVIEW;

ANIMALS; CELL LINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; EXOSOMES; HUMANS; MESENCHYMAL STROMAL CELLS;

EID: 84874988827     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.07.001     Document Type: Review

References (119)

1. Symon Z. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999, 86:72-78.
2. Perez A.T., Domenech G.H., Frankel C., Vogel C.L. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Invest. 2002, 20:22-29.
3. O'Shaughnessy J.A. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin. Breast Cancer 2003, 4:318-328.
4. Goncalves A. Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors. Anticancer Res. 2003, 23:3543-3548.
5. Harrington K.J. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur. J. Cancer 2001, 37:2015-2022.
6. Schmidinger M. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br. J. Cancer 2001, 85:1850-1852.
7. Schwonzen M., Kurbacher C.M., Mallmann P. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 2000, 11:681-685.
8. Seiden M.V. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol. Oncol. 2004, 93:229-232.
9. Skubitz K.M. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest. 2003, 21:167-176.
10. Wollina U. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003, 98:993-1001.
11. Johnston S.R., Gore M.E. Caelyx: phase II studies in ovarian cancer. Eur. J. Cancer 2001, 37:S8-S14.
12. Sundar S. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis. 2003, 37:800-804.
13. Grant G.J. A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia. Anesthesiology 2004, 101:133-137.
14. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
15. Yoo J.-W., Irvine D.J., Discher D.E., Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov. 2011, 10:521-535.
16. Simons M., Raposo G. Exosomes - vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 2009, 21:575-581.
17. van den Boorn J.G., Schlee M., Coch C., Hartmann G. SiRNA delivery with exosome nanoparticles. Nat. Biotechnol. 2011, 29:325-326.
18. Lakhal S., Wood M.J.A. Exosome nanotechnology: an emerging paradigm shift in drug delivery. Bioessays 2011, 33:737-741.
19. Pan B.T., Johnstone R.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983, 33:967-978.
20. Fevrier B., Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 2004, 16:415-421.
21. Wubbolts R., Leckie R.S., Veenhuizen P.T., Schwarzmann G., Mobius W., Hoernschemeyer J., Slot J.W., Geuze H.J., Stoorvogel W. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J. Biol. Chem. 2003, 278:10,963-10,972.
22. de Gassart A., Geminard C., Fevrier B., Raposo G., Vidal M. Lipid raft-associated protein sorting in exosomes. Blood 2003, 102:4336-4344.
23. Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., Geuze H.J. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996, 183:1161-1172.
24. Escola J.M., Kleijmeer M.J., Stoorvogel W., Griffith J.M., Yoshie O., Geuze H.J. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J. Biol. Chem. 1998, 273:20,121-20,127.
25. Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., Ricciardi-Castagnoli P., Raposo G., Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 1998, 4:594-600.
26. Pegtel D.M., Cosmopoulos K., Thorley-Lawson D.A., van Eijndhoven M.A., Hopmans E.S., Lindenberg J.L., de Gruijl T.D., Wurdinger T., Middeldorp J.M. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6328-6333.
27. Faure J., Lachenal G., Court M., Hirrlinger J., Chatellard-Causse C., Blot B., Grange J., Schoehn G., Goldberg Y., Boyer V., Kirchhoff F., Raposo G., Garin J., Sadoul R. Exosomes are released by cultured cortical neurones. Mol. Cell. Neurosci. 2006, 31:642-648.
28. Lachenal G., Pernet-Gallay K., Chivet M., Hemming F.J., Belly A., Bodon G., Blot B., Haase G., Goldberg Y., Sadoul R. Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol. Cell. Neurosci. 2011, 46:409-418.
29. Bakhti M., Winter C., Simons M. Inhibition of myelin membrane sheath formation by oligodendrocyte-derived exosome-like vesicles. J. Biol. Chem. 2011, 286:787-796.
30. Vrijsen K.R., Sluijter J.P.G., Schuchardt M.W.L., van Balkom B.W.M., Noort W.A., Chamuleau S.A.J., Doevendans P.A.F.M. Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells. J. Cell. Mol. Med. 2010, 14:1064-1070.
31. Miyado K., Yoshida K., Yamagata K., Sakakibara K., Okabe M., Wang X., Miyamoto K., Akutsu H., Kondo T., Takahashi Y., Ban T., Ito C., Toshimori K., Nakamura A., Ito M., Miyado M., Mekada E., Umezawa A. The fusing ability of sperm is bestowed by CD9-containing vesicles released from eggs in mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:12,921-12,926.
32. Lai R.C., Arslan F., Lee M.M., Sze N.S., Choo A., Chen T.S., Salto-Tellez M., Timmers L., Lee C.N., El Oakley R.M., Pasterkamp G., de Kleijn D.P., Lim S.K. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010, 4:214-222.
33. Bruno S., Grange C., Deregibus M.C., Calogero R.A., Saviozzi S., Collino F., Morando L., Busca A., Falda M., Bussolati B., Tetta C., Camussi G. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J. Am. Soc. Nephrol. 2009, 20:1053-1067.
34. Fevrier B., Vilette D., Archer F., Loew D., Faigle W., Vidal M., Laude H., Raposo G. Cells release prions in association with exosomes. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9683-9688.
35. Lenassi M., Cagney G., Liao M., Vaupotič T., Bartholomeeusen K., Cheng Y., Krogan N.J., Plemenitaš A., Peterlin B.M. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic 2010, 11:110-122.
36. Porto-Carreiro I., Fevrier B., Paquet S., Vilette D., Raposo G. Prions and exosomes: from PrPc trafficking to PrPsc propagation. Blood Cells Mol. Dis. 2005, 35:143-148.
37. Vallhov H., Gutzeit C., Johansson S.M., Nagy N., Paul M., Li Q., Friend S., George T.C., Klein E., Scheynius A., Gabrielsson S. Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro. J. Immunol. 2011, 186:73-82.
38. Bhatnagar S., Schorey J.S. Exosomes released from infected macrophages contain Mycobacterium avium glycopeptidolipids and are proinflammatory. J. Biol. Chem. 2007, 282:25,779-25,789.
39. Hao S., Ye Z., Li F., Meng Q., Qureshi M., Yang J., Xiang J. Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes. Exp. Oncol. 2006, 28:126-131.
40. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
41. Valenti R., Huber V., Filipazzi P., Pilla L., Sovena G., Villa A., Corbelli A., Fais S., Parmiani G., Rivoltini L. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-β-mediated suppressive activity on T lymphocytes. Cancer Res. 2006, 66:9290-9298.
42. Camussi G., Deregibus M.C., Bruno S., Grange C., Fonsato V., Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am. J. Cancer Res. 2011, 1:98-110.
43. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J.A. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29:341-345.
44. Simpson R.J., Jensen S.S., Lim J.W. Proteomic profiling of exosomes: current perspectives. Proteomics 2008, 8:4083-4099.
45. Thery C., Duban L., Segura E., Veron P., Lantz O., Amigorena S. Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat. Immunol. 2002, 3:1156-1162.
46. Andre F., Chaput N., Schartz N.E., Flament C., Aubert N., Bernard J., Lemonnier F., Raposo G., Escudier B., Hsu D.H., Tursz T., Amigorena S., Angevin E., Zitvogel L. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. 2004, 172:2126-2136.
47. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659.
48. Hood J.L., San R.S., Wickline S.A. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011, 71:3792-3801.
49. Peters P.J., Geuze H.J., Van Der Donk H.A., Slot J.W., Griffith J.M., Stam N.J., Clevers H.C., Borst J. Molecules relevant for T cell-target cell interaction are present in cytolytic granules of human T lymphocytes. Eur. J. Immunol. 1989, 19:1469-1475.
50. Heijnen H.F.G., Schiel A.E., Fijnheer R., Geuze H.J., Sixma J.J. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α-granules. Blood 1999, 94:3791-3799.
51. Wolfers J., Lozier A., Raposo G., Regnault A., Théry C., Masurier C., Flament C., Pouzieux S., Faure F., Tursz T., Angevin E., Amigorena S., Zitvogel L. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001, 7:297-303.
52. Sokolova V., Ludwig A.-K., Hornung S., Rotan O., Horn P.A., Epple M., Giebel B. Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf. B Biointerfaces 2011, 87:146-150.
53. Clayton A., Al-Taei S., Webber J., Mason M.D., Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J. Immunol. 2011, 187:676-683.
54. Sullivan R., Saez F., Girouard J., Frenette G. Role of exosomes in sperm maturation during the transit along the male reproductive tract. Blood Cells Mol. Dis. 2005, 35:1-10.
55. Mathivanan S., Ji H., Simpson R.J. Exosomes: extracellular organelles important in intercellular communication. J. Proteomics 2010, 73:1907-1920.
56. Thery C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2:569-579.
57. Stoorvogel W., Kleijmeer M.J., Geuze H.J., Raposo G. The biogenesis and functions of exosomes. Traffic 2002, 3:321-330.
58. Pisitkun T., Shen R.F., Knepper M.A. Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:13,368-13,373.
59. Andre F., Schartz N.E., Movassagh M., Flament C., Pautier P., Morice P., Pomel C., Lhomme C., Escudier B., Le Chevalier T., Tursz T., Amigorena S., Raposo G., Angevin E., Zitvogel L. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002, 360:295-305.
60. Dai S., Wan T., Wang B., Zhou X., Xiu F., Chen T., Wu Y., Cao X. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin. Cancer Res. 2005, 11:7554-7563.
61. Clayton A., Mitchell J.P., Court J., Mason M.D., Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 2007, 67:7458-7466.
62. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110:13-21.
63. Mathivanan S., Fahner C.J., Reid G.E., Simpson R.J. ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res. 2012, 40:D1241-D1244.
64. Hunter M.P., Ismail N., Zhang X., Aguda B.D., Lee E.J., Yu L., Xiao T., Schafer J., Lee M.L.T., Schmittgen T.D., Nana-Sinkam S.P., Jarjoura D., Marsh C.B. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3.
65. Rabinowits G., Gerçel-Taylor C., Day J.M., Taylor D.D., Kloecker G.H. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10:42-46.
66. Kosaka N., Iguchi H., Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101:2087-2092.
67. Kern S., Eichler H., Stoeve J., Kluter H., Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006, 24:1294-1301.
68. Banas A., Teratani T., Yamamoto Y., Tokuhara M., Takeshita F., Quinn G., Okochi H., Ochiya T. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 2007, 46:219-228.
69. Arai F., Ohneda O., Miyamoto T., Zhang X.Q., Suda T. Mesenchymal stem cells in perichondrium express activated leukocyte cell adhesion molecule and participate in bone marrow formation. J. Exp. Med. 2002, 195:1549-1563.
70. In 't Anker P.S., Noort W.A., Scherjon S.A., Kleijburg-Van der Keur C., Kruisselbrink A.B., Van Bezooijen R.L., Beekhuizen W., Willemze R., Kanhai H.H.H., Fibbe W.E. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 2003, 88:845-852.
71. Young H.E., Steele T.A., Bray R.A., Hudson J., Floyd J.A., Hawkins K., Thomas K., Austin T., Edwards C., Cuzzourt J., Duenzl M., Lucas P.A., Black A.C. Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat. Rec. 2001, 264:51-62.
72. Roubelakis M.G., Pappa K.I., Bitsika V., Zagoura D., Vlahou A., Papadaki H.A., Antsaklis A., Anagnou N.P. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev. 2007, 16:931-952.
73. Fukuchi Y., Nakajima H., Sugiyama D., Hirose I., Kitamura T., Tsuji K. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 2004, 22:649-658.
74. Miao Z., Jin J., Chen L., Zhu J., Huang W., Zhao J., Qian H., Zhang X. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell Biol. Int. 2006, 30:681-687.
75. Brooke G., Cook M., Blair C., Han R., Heazlewood C., Jones B., Kambouris M., Kollar K., McTaggart S., Pelekanos R., Rice A., Rossetti T., Atkinson K. Therapeutic applications of mesenchymal stromal cells. Semin. Cell Dev. Biol. 2007, 18:846-858.
76. Huang G.T.J., Gronthos S., Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in Regenerative Medicine. J. Dent. Res. 2009, 88:792-806.
77. Lai R.C., Arslan F., Tan S.S., Tan B., Choo A., Lee M.M., Chen T.S., Teh B.J., Eng J.K., Sidik H., Tanavde V., Hwang W.S., Lee C.N., El Oakley R.M., Pasterkamp G., de Kleijn D.P., Tan K.H., Lim S.K. Derivation and characterization of human fetal MSCs: an alternative cell source for large-scale production of cardioprotective microparticles. J. Mol. Cell. Cardiol. 2010, 48:1215-1224.
78. Lian Q., Lye E., Suan Yeo K., Khia Way Tan E., Salto-Tellez M., Liu T.M., Palanisamy N., El Oakley R.M., Lee E.H., Lim B., Lim S.K. Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells 2007, 25:425-436.
79. Bernardo M.E., Pagliara D., Locatelli F. Mesenchymal stromal cell therapy: a revolution in regenerative medicine?. Bone Marrow Transplant. 2012, 47:164-171.
80. Salem H.K., Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010, 28:585-596.
81. Abdallah B.M., Kassem M. Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther. 2008, 15:109-116.
82. Lee R.H., Kim B., Choi I., Kim H., Choi H.S., Suh K., Bae Y.C., Jung J.S. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell. Physiol. Biochem. 2004, 14:311-324.
83. Giordano A., Galderisi U., Marino I.R. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J. Cell. Physiol. 2007, 211:27-35.
84. Le Blanc K., Pittenger M.F. Mesenchymal stem cells: progress toward promise. Cytotherapy 2005, 7:36-45.
85. Ankrum J., Karp J.M. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol. Med. 2010, 16:203-209.
86. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., Gerstenblith G., DeMaria A.N., Denktas A.E., Gammon R.S., Hermiller J.B., Reisman M.A., Schaer G.L., Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 2009, 54:2277-2286.
87. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberger M., Dini G., Egeler R.M., Bacigalupo A., Fibbe W., Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
88. Duijvestein M., Vos A.C.W., Roelofs H., Wildenberg M.E., Wendrich B.B., Verspaget H.W., Kooy-Winkelaar E.M.C., Koning F., Zwaginga J.J., Fidder H.H., Verhaar A.P., Fibbe W.E., Van Den Brink G.R., Hommes D.W. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010, 59:1662-1669.
89. Wright K.T., El Masri W., Osman A., Chowdhury J., Johnson W.E.B. Concise review: bone marrow for the treatment of spinal cord injury: mechanisms and clinical applications. Stem Cells 2011, 29:169-178.
90. Bhansali A., Upreti V., Khandelwal N., Marwaha N., Gupta V., Sachdeva N., Sharma R.R., Saluja K., Dutta P., Walia R., Minz R., Bhadada S., Das S., Ramakrishnan S. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells Dev. 2009, 18:1407-1415.
91. Phinney D.G., Prockop D.J. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - current views. Stem Cells 2007, 25:2896-2902.
92. Iso Y., Spees J.L., Serrano C., Bakondi B., Pochampally R., Song Y.H., Sobel B.E., Delafontaine P., Prockop D.J. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem. Biophys. Res. Commun. 2007, 354:700-706.
93. da Silva Meirelles L., Caplan A.I., Nardi N.B. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008, 26:2287-2299.
94. Dai W., Hale S.L., Martin B.J., Kuang J.Q., Dow J.S., Wold L.E., Kloner R.A. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation 2005, 112:214-223.
95. Noiseux N., Gnecchi M., Lopez-Ilasaca M., Zhang L., Solomon S.D., Deb A., Dzau V.J., Pratt R.E. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol. Ther. 2006, 14:840-850.
96. Katsha A.M., Ohkouchi S., Xin H., Kanehira M., Sun R., Nukiwa T., Saijo Y. Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol. Ther. 2011, 19:196-203.
97. Horwitz E.M., Gordon P.L., Koo W.K.K., Marx J.C., Neel M.D., McNall R.Y., Muul L., Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8932-8937.
98. Toma C., Pittenger M.F., Cahill K.S., Byrne B.J., Kessler P.D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002, 105:93-98.
99. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 2006, 98:1076-1084.
100. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., Mu H., Melo L.G., Pratt R.E., Ingwall J.S., Dzau V.J. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006, 20:661-669.
101. Timmers L., Lim S.-K., Arslan F., Armstrong J.S., Hoefler I.E., Doevendans P.A., Piek J.J., El Oakley R.M., Choo A., Lee C.N., Pasterkamp G., de Kleijn D.P.V. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res. 2008, 1:129-137.
102. Togel F., Hu Z., Weiss K., Isaac J., Lange C., Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Renal Physiol. 2005, 289:F31-F42.
103. Chen L., Tredget E.E., Wu P.Y., Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008, 3:e1886.
104. Arthur A., Zannettino A., Gronthos S. The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J. Cell. Physiol. 2009, 218:237-245.
105. Humphreys B.D., Bonventre J.V. Mesenchymal stem cells in acute kidney injury. Annu. Rev. Med. 2008, 59:311-325.
106. Patel K.M., Crisostomo P., Lahm T., Markel T., Herring C., Wang M., Meldrum K.K., Lillemoe K.D., Meldrum D.R. Mesenchymal stem cells attenuate hypoxic pulmonary vasoconstriction by a paracrine mechanism. J. Surg. Res. 2007, 143:281-285.
107. Gnecchi M., He H., Liang O.D., Melo L.G., Morello F., Mu H., Noiseux N., Zhang L., Pratt R.E., Ingwall J.S., Dzau V.J. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat. Med. 2005, 11:367-368.
108. Timmers L., Lim S.K., Hoefer I.E., Arslan F., Lai R.C., van Oorschot A.A.M., Goumans M.J., Strijder C., Sze S.K., Choo A., Piek J.J., Doevendans P.A., Pasterkamp G., de Kleijn D.P.V. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res. 2011, 6:206-214.
109. Marigo I., Dazzi F. The immunomodulatory properties of mesenchymal stem cells. Semin. Immunopathol. 2011, 33:593-602.
110. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 2003, 171:3426-3434.
111. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75:389-397.
112. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A., Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 2002, 30:42-48.
113. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
114. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 2003, 57:11-20.
115. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
116. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., Risso M., Gualandi F., Mancardi G.L., Pistoia V., Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
117. Chen T.S., Arslan F., Yin Y., Tan S.S., Lai R.C., Choo A.B., Padmanabhan J., Lee C.N., de Kleijn D.P., Lim S.K. Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. J. Transl. Med. 2011, 9:47.
118. Lai R.C., Chen T.S., Lim S.K. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen. Med. 2011, 6:481-492.
119. Li G., Luo R., Zhang J., Yeo K.S., Lian Q., Xie F., Tan E.K., Caille D., Kon O.L., Salto-Tellez M., Meda P., Lim S.K. Generating mESC-derived insulin-producing cell lines through an intermediate lineage-restricted progenitor line. Stem Cell Res. 2009, 2:41-55.